See package insert. How to take and store Felbamate? Follow your doctor’s directions. Call if you have any questions. Usually, your doctor will tell you to start by. Felbatol is the brand name used in the United States for felbamate. Read the black box warning in the Package Insert to your patient and obtain any necessary . Felbamate, also known as Felbatol, has been approved by the Food and Drug about all potential risks before using this drug and read the package insert.
|Published (Last):||7 March 2008|
|PDF File Size:||8.24 Mb|
|ePub File Size:||20.53 Mb|
|Price:||Free* [*Free Regsitration Required]|
Moderate Concomitant use of systemic lidocaine and felbamate may decrease lidocaine plasma concentrations. Moderate Use lacosamide with caution in patients taking concomitant medications that affect cardiac conduction including those that prolong PR interval, such as sodium channel blocking anticonvulsants e.
Monitor for antiviral efficacy if these drugs are administered together. Cobicistat; Elvitegravir; Emtricitabine; Tenofovir Alafenamide: The relative risk for suicidality was higher in patients with epilepsy compared to those with other conditions; however, the absolute risk differences were similar in trials for epilepsy and psychiatric indications.
Felbamate increases the steady-state serum ibsert of phenobarbital. Minor Bone marrow suppression is associated with guanidine therapy.
Monitoring of the anticonvulsant serum concentration is recommended. Felbamate is a CYP3A4 inducer, which may result in decreased bedaquiline systemic exposure AUC and possibly reduced therapeutic effect.
Serum concentrations of other anticonvulsants should feobamate obtained and dosage adjustments made as necessary. Avoid concomitant use of other drugs known to cause bone marrow suppression such as felbamate.
Felbatol (felbamate) dose, indications, adverse effects, interactions from
The need for indefinite continuation in treating any condition pckage be based on confirmation of the condition and its potential cause s. Because of the serious toxicities associated with the drug, including aplastic anemia and hepatic failure, breast-feeding should generally be avoided during treatment with felbamate. The drug is not recommended for children under the age of 2 years or in infants.
However, this is considered to be a class effect.
The increased risk of suicidal ideation and behavior was observed between 1 and 24 weeks after therapy initiation. Agents that induce CYP3A4 may increase the metabolism of vincristine and decrease the efficacy of drug, including felbamate. paclage
Major Concurrent administration packagd felbamate with dasabuvir; ombitasvir; paritaprevir; ritonavir may result in decreased plasma concentrations of dasabuvir, paritaprevir, and ritonavir. Too little is known about felbamate-induced aplastic anemia to determine fatality percentages or feblamate patients are more at risk for this serious adverse reaction. Felbamate may interfere with valproic acid metabolism and should be administered cautiously to patients receiving valproic acid.
Major Maprotiline, when used concomitantly with anticonvulsants, can increase CNS depression and may also lower the seizure threshold, leading packzge pharmacodynamic interactions. Dosage adjustment of methsuximide may be required. Use felbamate with caution in patients with pre-existing renal impairment, particularly renal failure. Avoid coadministration of felbamate and doxorubicin if possible.
It is similar for both the tablets and suspension. Monitor concentrations of normethsuximide in patients treated with methsuximide and felbamate. No systematic studies of felbamate in geriatric patients have been conducted. Moderate Amoxapine, when used concomitantly with anticonvulsants, can increase CNS depression and may also lower the seizure threshold, leading to pharmacodynamic interactions.
Pckage not restart felbamate in these patients. For the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children.
The anticonvulsants mentioned may cause oral contraceptive failure, especially when low-dose estrogen regimens e. In rats, there was a decrease in pup weight and an increase in pup deaths during lactation; the reason for the deaths is not determined. Taking these drugs together may decrease velpatasvir plasma concentrations, potentially resulting in loss of antiviral efficacy.
According to the Beers Criteria, anticonvulsants such as felbamate are considered potentially inappropriate medications PIMs in geriatric patients with a history of falls or fractures and should be avoided in these patient populations, with the exception of treating seizure and mood disorders, since anticonvulsants can produce ataxia, impaired psychomotor function, syncope, and additional falls. There are no studies in pregnant women to determine the effect of felbamate on the fetus. Felbamate should be discontinued if signs and symptoms of hematologic abnormalities or any sign of bone marrow depression occurs.
Moderate If concurrent use of cobimetinib and felbamate is necessary, use caution and monitor for decreased efficacy of cobimetinib. Major Avoid concomitant use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis, such as felbamate; however, if this is not possible, closely monitor the absolute neutrophil count and interrupt deferiprone therapy if neutropenia develops.
Felbamate may cause hepatotoxicity and hepatic failure. If these drugs must be administered together, closely monitor for a reduction in dapsone efficacy and signs of hemolytic anemia. Indert patients for adverse reactions and breakthrough fungal infections if these drugs are coadministered. Major Estrogens and progestins are both susceptible to drug interactions with hepatic enzyme inducing drugs.
Additionally, patients taking non-oral combination contraceptives or estrogens or progestins for hormone replacement therapy may also experience reduced clinical efficacy; dosage adjustments may be necessary.
Major Based on very limited data, it appears felbamate can accelerate the clearance of the estrogen component of some oral contraceptives.
Major Coadministration of felbamate and clarithromycin may decrease clarithromycin serum concentrations due to CYP3A4 enzyme induction. The binding of glycine to the NMDA receptor causes an increase in the frequency of NMDA receptor-mediated channel opening, which is important in the initiation and propagation of seizures.
Clinically significant interactions have been reported when doxorubicin was coadministered with inhibitors of CYP3A4, resulting in increased concentration and clinical effect of doxorubicin. The dosage reduction of other AEDs will help maintain plasma concentrations and reduce side effects of concurrent phenytoin, valproic acid, or carbamazepine and its metabolites.
If not possible, closely monitor for increased side effects of doxorubicin including myelosuppression and cardiotoxicity.
Felbamate is contraindicated in patients with current or previous hepatic disease or dysfunction e.